Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,774
datasets available to search
ShareScore release 0.9.0
Dataset results
2,774 results for “Agent”
Alteration of miRNome by recombinant ncRNA agents
GEO Series GSE103349. Homo sapiens. 18 samples. Type: Non-coding RNA profiling by high throughput sequencing.
Monotherapy of the DNA Hypomethylating Agent, NTX301 Targets Ovarian Cancer
GEO Series GSE236986. Homo sapiens. 12 samples. Type: Expression profiling by high throughput sequencing; Methylation profiling by array.
Viral Agents and Systemic Levels of Inflammatory Cytokines in Vulnerable and Stable Atherosclerotic Carotid Plaques
<p>Mazzaccaro D, Dolci M, Perego F, Delbue S, Giannetta M, Cardani R, Valentina Renna L, Costa E, Corsi-Romanelli MM, Galli C, Pariani E, Nano G, Clemente C, Basilico N. Viral Agents and Systemic Levels of Inflammatory Cytokines in Vulnerable and Stable Atherosclerotic Carotid Plaques. Ann Vasc Surg. 2021 Dec 11:S0890-5096(21)00912-2. doi: 10.1016/j.avsg.2021.10.070. Epub ahead of print. PMID: 34902464.</p> <p>Abstract</p> <p><strong>Background: </strong>To investigate the presence of genetic material of viral agents and the serum level of inflammatory cytokines in patients submitted to carotid endarterectomy having vulnerable versus stable atherosclerotic plaques.</p> <p><strong>Methods: </strong>Data of patients consecutively submitted to carotid endarterectomy for a significant stenosis from July 2019 to December 2019 were prospectively collected. The genetic material of Epstein-Barr (EBV), CitoMegalo (CMV), Herpes Simplex (HSV), Varicella-Zoster (VZV) and Influenza (IV) Viruses was searched in the patient's plaques, both in the "mid" of the plaque and in an adjacent lateral portion of no-plaque area. The serum levels of TNF-α, IL-1β, IL-6, IL10 and CCL5 were determined. The obtained results were then correlated to the histologic vulnerability of the removed carotid plaque. P values < 0.05 were considered statistically significant.</p> <p><strong>Results: </strong>Data of 50 patients were analyzed. A vulnerable plaque was found in 31 patients (62%). The genome of CMV, HSV, VZV and IV was not found in any of the vascular samples, while the EBV genome was found in the "mid" of 2 vulnerable plaques, but not in their respective control area. Eighty-two percent of patients who did not receive anti-IV vaccination (23/28) had vulnerable carotid plaque, compared with 36% of vaccinated patients (8/22, P = 0.001). Serum levels of TNF-α and IL-6 were higher in patients with a vulnerable plaque compared to patients with a stable plaque (73.6 ± 238.2 vs. 3.9 ± 13.1 pg/ml, P= 0.01, and 45.9 ± 103.6 vs. 10.1 ± 25.3 pg/ml, P= 0.01, respectively), independent of comorbidities, viral exposure or flu vaccination.</p> <p><strong>Conclusions: </strong>The EBV genome was found in the "core" of 2 vulnerable carotid plaques, but not in their respective adjacent control. Influenza vaccination was associated with a lower incidence of carotid plaque vulnerability. Serum levels of TNF-α and IL-6 were higher in patients with a vulnerable plaque compared to patients with a stable plaque.</p>
Data related to freeze-thaw experiments with bacteria-based healing agent
<p>Open data concerning experimental work. The paper presents the benefits of introducing a bacteria-based healing agent in concrete to enable self-healing, assessed under frost salt scaling conditions. Durability tests such as scaling, water permeability and chloride ingress were performed. In addition, a microstructural analysis based on mercury intrusion porosimetry (MIP), fluorescence microscopy, thin section analysis, scanning electron microscopy (SEM) and energy-dispersive X-ray (EDX) spectroscopy was performed. </p>
Viral Agents and Systemic Levels of Inflammatory Cytokines in Vulnerable and Stable Atherosclerotic Carotid Plaques
<p>Mazzaccaro D, Dolci M, Perego F, Delbue S, Giannetta M, Cardani R, Valentina Renna L, Costa E, Corsi-Romanelli MM, Galli C, Pariani E, Nano G, Clemente C, Basilico N. Viral Agents and Systemic Levels of Inflammatory Cytokines in Vulnerable and Stable Atherosclerotic Carotid Plaques. Ann Vasc Surg. 2022 May;82:325-333. doi: 10.1016/j.avsg.2021.10.070. Epub 2021 Dec 11. PMID: 34902464.</p> <p>Abstract</p> <p><strong>Background: </strong>To investigate the presence of genetic material of viral agents and the serum level of inflammatory cytokines in patients submitted to carotid endarterectomy having vulnerable versus stable atherosclerotic plaques.</p> <p><strong>Methods: </strong>Data of patients consecutively submitted to carotid endarterectomy for a significant stenosis from July 2019 to December 2019 were prospectively collected. The genetic material of Epstein-Barr (EBV), CitoMegalo (CMV), Herpes Simplex (HSV), Varicella-Zoster (VZV) and Influenza (IV) Viruses was searched in the patient's plaques, both in the "mid" of the plaque and in an adjacent lateral portion of no-plaque area. The serum levels of TNF-α, IL-1β, IL-6, IL10 and CCL5 were determined. The obtained results were then correlated to the histologic vulnerability of the removed carotid plaque. P values < 0.05 were considered statistically significant.</p> <p><strong>Results: </strong>Data of 50 patients were analyzed. A vulnerable plaque was found in 31 patients (62%). The genome of CMV, HSV, VZV and IV was not found in any of the vascular samples, while the EBV genome was found in the "mid" of 2 vulnerable plaques, but not in their respective control area. Eighty-two percent of patients who did not receive anti-IV vaccination (23/28) had vulnerable carotid plaque, compared with 36% of vaccinated patients (8/22, P = 0.001). Serum levels of TNF-α and IL-6 were higher in patients with a vulnerable plaque compared to patients with a stable plaque (73.6 ± 238.2 vs. 3.9 ± 13.1 pg/ml, P= 0.01, and 45.9 ± 103.6 vs. 10.1 ± 25.3 pg/ml, P= 0.01, respectively), independent of comorbidities, viral exposure or flu vaccination.</p> <p><strong>Conclusions: </strong>The EBV genome was found in the "core" of 2 vulnerable carotid plaques, but not in their respective adjacent control. Influenza vaccination was associated with a lower incidence of carotid plaque vulnerability. Serum levels of TNF-α and IL-6 were higher in patients with a vulnerable plaque compared to patients with a stable plaque.</p>
Viral Agents and Systemic Levels of Inflammatory Cytokines in Vulnerable and Stable Atherosclerotic Carotid Plaques
<p>Mazzaccaro D, Dolci M, Perego F, Delbue S, Giannetta M, Cardani R, Valentina Renna L, Costa E, Corsi-Romanelli MM, Galli C, Pariani E, Nano G, Clemente C, Basilico N. Viral Agents and Systemic Levels of Inflammatory Cytokines in Vulnerable and Stable Atherosclerotic Carotid Plaques. Ann Vasc Surg. 2022 May;82:325-333. doi: 10.1016/j.avsg.2021.10.070. Epub 2021 Dec 11. PMID: 34902464.</p> <p>Abstract</p> <p><strong>Background: </strong>To investigate the presence of genetic material of viral agents and the serum level of inflammatory cytokines in patients submitted to carotid endarterectomy having vulnerable versus stable atherosclerotic plaques.</p> <p><strong>Methods: </strong>Data of patients consecutively submitted to carotid endarterectomy for a significant stenosis from July 2019 to December 2019 were prospectively collected. The genetic material of Epstein-Barr (EBV), CitoMegalo (CMV), Herpes Simplex (HSV), Varicella-Zoster (VZV) and Influenza (IV) Viruses was searched in the patient's plaques, both in the "mid" of the plaque and in an adjacent lateral portion of no-plaque area. The serum levels of TNF-α, IL-1β, IL-6, IL10 and CCL5 were determined. The obtained results were then correlated to the histologic vulnerability of the removed carotid plaque. P values < 0.05 were considered statistically significant.</p> <p><strong>Results: </strong>Data of 50 patients were analyzed. A vulnerable plaque was found in 31 patients (62%). The genome of CMV, HSV, VZV and IV was not found in any of the vascular samples, while the EBV genome was found in the "mid" of 2 vulnerable plaques, but not in their respective control area. Eighty-two percent of patients who did not receive anti-IV vaccination (23/28) had vulnerable carotid plaque, compared with 36% of vaccinated patients (8/22, P = 0.001). Serum levels of TNF-α and IL-6 were higher in patients with a vulnerable plaque compared to patients with a stable plaque (73.6 ± 238.2 vs. 3.9 ± 13.1 pg/ml, P= 0.01, and 45.9 ± 103.6 vs. 10.1 ± 25.3 pg/ml, P= 0.01, respectively), independent of comorbidities, viral exposure or flu vaccination.</p> <p><strong>Conclusions: </strong>The EBV genome was found in the "core" of 2 vulnerable carotid plaques, but not in their respective adjacent control. Influenza vaccination was associated with a lower incidence of carotid plaque vulnerability. Serum levels of TNF-α and IL-6 were higher in patients with a vulnerable plaque compared to patients with a stable plaque.</p>
Real-time MRI monitoring of liquid embolic agent (Onyx) injection in a swine arteriovenous malformation model.
<p><br> </p> <p><strong>Movie 1 Real-time, dynamic EPI-GRE T2 scan of the whole brain volume during Onyx injection. Cine sequence of the ONYX propagation at the level of the pons. Dark liquid embolic agent is gradually filling small arteries around the pons. </strong></p> <p> </p> <p><strong>Movie 2 Real-time dynamic EPI-GRE MRI monitoring of the test infusion of diluted gadolinium (10mM) seen as a short wash-in and wash-out of hypointense signal, confirming the proper position of the microcatheter and verifying the area of trans-catheter perfusion.</strong></p>
Experiments for "Time-varying formation tracking for second order multi-agent systems: an experimental approach for wheeled robots"
<p>In this paper, a time-varying formation tracking protocol for second order Multi-Agent 1<br> Systems (MASs) is presented. The time-varying formation considers translation, rotation and scaling 2<br> of the geometric pattern that defines the formation. The control law is simple yet effective, and is 3<br> composed of a trajectory tracking control and a consensus control that considers position and velocity 4<br> feedback of the connected agents in the MAS. The closed-loop system is asymptotically stable, and 5<br> this is proved using the Gershgoring’s disk theorem. The performance of the protocol is extensively 6<br> tested in experiments using a dynamic extension of the differential-drive robot model. The protocol 7<br> is tested for different communication topologies and also deals with switching topologies. The 8<br> proposed protocol presents good performance to both time-varying formation and topology changes. 9<br> Moreover, a comparison with an existing controller and with only trajectory tracking control is 10<br> provided, showing that the proposed protocol preserves in a better way the formation for all the 11<br> tested topologies.</p>
Discovery of myrsinane diterpenoids from Euphorbia prolifera as a new type of anti-liver fibrosis agents that inhibit PI3K-AKT signaling pathway
GEO Series GSE314666. Homo sapiens. 6 samples. Type: Expression profiling by high throughput sequencing.
Alteration of transcriptome by recombinant ncRNA agents
GEO Series GSE104442. Homo sapiens. 18 samples. Type: Expression profiling by high throughput sequencing.
Stereoselective RNA Reaction with Chiral 2'-OH Acylating Agents
GEO Series GSE247565. synthetic construct. 10 samples. Type: Other.
Monotherapy of the DNA Hypomethylating Agent, NTX301 Targets Ovarian Cancer (RNA-Seq)
GEO Series GSE236985. Homo sapiens. 6 samples. Type: Expression profiling by high throughput sequencing.
Non-erythroid heme biosynthesis gene, ALAS1, up-regulation after hypomethylating agents predict better outcome in patients with myelodysplastic syndrome
<p>Supplementary Figure: mRNA next generation sequence analysis. (A) mRNA expression of MDS patients treated with AZA. MDS001: MDS with early AZA treatment failure. MDS001_1: before AZA treatment; MDS001_2: under AZA treatment, with response; MDS001_3: AZA treatment failure with leukemia change. MDS002: AZA failure within 2 years. MDS002_1: before treatment; MDS002_2: under AZA treatment, with response. MDS003: long-term AZA treatment response; MDS001: MDS001-1+MDS001-2+MDS001-3. MDS002: MDS002-1 + MDS002-2. MDS003 is MDS003-1</p>
PRV is the causative agent of HSMI
<p>Data from challenge trial #1 and #2</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.